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A B S T R A C T
Background
As chronic obstructive pulmonary disease (COPD) progresses, exacerbations can occur with increasing frequency. One goal of therapy
in COPD is to try and prevent these exacerbations, thereby reducing disease morbidity and associated healthcare costs. Pneumococcal
vaccinations are considered to be one strategy for reducing the risk of infective exacerbations.
Objectives
To determine the safety and efficacy of pneumococcal vaccination in COPD. The primary outcome assessed was acute exacerbations.
Secondary outcomes of interest included episodes of pneumonia, hospital admissions, adverse events related to treatment, disability,
change in lung function, mortality, and cost effectiveness.
Search strategy
We searched the Cochrane Airways Group COPD trials register using pre-specified terms. We also conducted additional handsearches
of conference abstracts. The last round of searches were performed in April 2006.
Selection criteria
Only randomised controlled trials assessing the effects of injectable pneumococcal vaccine in people with COPD were included.
Data collection and analysis
Two review authors independently extracted data and three review authors independently assessed trial quality.
Main results
Although 10 studies cited in 11 publications were identified that met the inclusion criteria for this review, only four of these provided
data on participants with COPD. The studies which did provide data for this review consisted of two trials using a 14-valent vaccine,
and two using a 23-valent injectable vaccine.
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Data for the primary outcome, acute exacerbation of COPD, was available from only one of the four studies. The odds ratio of 1.43
(95% confidence interval (CI) 0.31 to 6.69) between interventions was not statistically significant.
Of the secondary outcomes for which data were available and could be extracted, none reached statistical significance. Three studies
provided dichotomous data for persons who developed pneumonia (OR 0.89, 95% CI 0.58 to 1.37, n = 748). Rates of hospital
admissions and emergency department visits came from a single study. There was no significant reduction in the odds of all-cause
mortality 1 to 48 months post-vaccination (Peto odds ratio 0.94, 95% CI 0.67 to 1.33, n = 888), or for death from cardiorespiratory
causes (OR 1.07, 95% CI 0.69 to 1.66).
Authors’ conclusions
There is no evidence from randomised controlled trials that injectable pneumococcal vaccination in personswithCOPDhas a significant
impact on morbidity or mortality. Further large randomised controlled trials would be needed to ascertain if the small benefits suggested
by individual studies are real.
P L A I N L A N G U A G E S U M M A R Y
Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
There is strong evidence that vaccines can protect healthy persons against infection by the pneumococcus bacteria, but little is known
about the effectiveness of the vaccine in persons with chronic obstructive pulmonary disease (COPD). The results from the four
randomised controlled trials included in this review with 941 participants do not show that pneumococcal vaccination provides
significant protection against disease caused by the bacteria.
B A C K G R O U N D
Chronic obstructive pulmonary disease (COPD) is a common
disease of older people characterised by airflow obstruction that
is largely irreversible. According to World Health Organization
estimates, COPD is the fourth leading cause of death worldwide
resulting in more than 2.7million deaths in 2000 (NHLBI 2001).
As the disease progresses, exacerbations, some of which are infec-
tive in origin, can occur several times per year, and may require
hospital admission. These exacerbations can take several weeks to
resolve, and during this time cause considerable morbidity as well
as leading to significant health care costs. Medicines have a lim-
ited role in the treatment of acute exacerbations and strategies that
reduce exacerbation rates are therefore very appealing.
To reduce the burden of illness, pneumococcal vaccination is
recommended by the major COPD guidelines (Balter 1994;
NCCCC 2004), although it is not endorsed by some authorities
(Chapman 1991; BTS 1997; Pauwels 2001). This recommenda-
tion appears to have been based largely on results of the efficacy
of pneumococcal vaccination in observational studies in general
populations, and in randomised clinical trials (RCT) in persons
without COPD. Pneumococcal infection is a major cause of pneu-
monia, resulting in over one million deaths per year worldwide.
Streptococcus pneumoniae (pneumococcus) is one of two organ-
isms commonly isolated from the sputum during exacerbations of
COPD, the other being Haemophilus influenzae. Both a large in-
direct cohort study (Butler 1993) and a meta-analysis (Fine 1994)
of pneumococcal vaccination have confirmed protection against
invasive bacteraemic disease.
This systematic review evaluates the evidence for the efficacy of
injectable pneumococcal vaccines in persons with COPD in ran-
domised and controlled clinical trials.
O B J E C T I V E S
1. To determine if pneumococcal vaccination reduces respiratory
illness (acute exacerbations of COPD or pneumonia) in people
with COPD.
2. To ascertain whether pneumococcal vaccination in people with
COPD is associated with excess adverse events.
3. To ascertain whether pneumococcal vaccination in people with
COPD reduces mortality.
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4. To ascertain whether pneumococcal vaccination in people with
COPD reduces health care costs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCT) using injectable pneu-
mococcal vaccines were included in the review.
Types of participants
Adults with COPD defined by the American Thoracic Society
(ATS 1995). This statement recognises people with a significant
smoking history are at risk of developing COPD and fundamental
to the diagnosis is the demonstration of airflow obstruction by
lung function testing. This is demonstrated by spirometric mea-
sures; Forced expiratory volume in one second (FEV1)/Forced vi-
tal capacity (FVC) < 0.7 and FEV1 < 80% predicted.
Types of interventions
At least one injectable pneumococcal vaccination.
Types of outcome measures
The outcomes sought in the trials are divided into those of primary
and secondary interest.
Primary outcomes
The number of acute exacerbations of COPD, defined as an in-
crease in breathlessness and/or volume and/or purulence of spu-
tum.
Secondary outcomes
1. The number of episodes of pneumonia.
2. The number of hospital admissions or visits to the
emergency department.
3. Mortality in the year following vaccination. This may
include mortality from respiratory disease, all causes, and causes
other than respiratory disease.
4. The number of days of disability from respiratory illness
variously defined as days in bed, days off work or days when the
participant was unable to undertake normal activities.
5. Change in lung function.
6. Adverse effects of treatment.
7. Costs of pneumococcal vaccination (including acquisition,
cost savings, health economics).
Search methods for identification of studies
We identified RCTs using the Cochrane Airways Group Spe-
cialisedRegister of trialswhich is derived from systematic searching
of electronic databases including CENTRAL, MEDLINE, EM-
BASE and CINAHL, and handsearching of respiratory journals
and meeting abstracts.
We searched all records in the Specialised Register coded as
’COPD’ using the following terms:
(vaccin* or immuni*) and pneum*
An advanced search of the Cochrane Central Register of Con-
trolled Trials (CENTRAL) was also carried out using these terms.
From the full text papers obtained, we searched the bibliographic
lists for additional articles.
Searches are current as of April 2006.
Data collection and analysis
We obtained the full text version of all identified articles for as-
sessment of relevance. From the full text articles, the two review
authors (PM or RG and RWB) independently established whether
each study met the inclusion criteria as a RCT or CCT of pneu-
mococcal vaccination in COPD, and that some data on one of
the primary endpoints were included in the paper. The percentage
agreement was recorded and disagreement was resolved by discus-
sion between the two review authors.
It was anticipated that the follow-up period in the trials would be
12 months. If this was not the case, event rates were corrected as
if they applied to a 12 month period, although this assumes that
the event rate is constant over that time period.
Three review authors (RWB, RHG, JW) agreed the format of the
data extraction sheets. Data was extracted by two review authors
(RWB, RHG) to data extraction sheets of an agreed format, and
then entered intoRevMan4.2. A third review author (JW) verified
data extraction. Two review authors (RHG, JW) independently
double-checked each entry.
Assessment of Study Quality
Three review authors (RWB, RHG, JW) independently assessed
quality by three review authors (RWB,RHG, JW)using twometh-
ods. First, using the Cochrane approach to assessment of alloca-
tion concealment, all trials were scored and entered according to
the following variables:
A: ADEQUATE if there was true randomisation i.e. a central
randomisation scheme, randomisation by external person or use
of coded containers/envelopes;
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B: UNCLEAR it is not possible to establish the method of allo-
cation concealment based on the published article and/or from
correspondence with the trialists;
C: INADEQUATE if there was alternate allocation, reference to
case record number, date of birth, day of the week, or an open test
or random numbers;
D. NOT RANDOMISED e.g. a case control or cohort study
In addition, we assessed each study using a scale (scores 0 to 5)
based upon the method described by Jadad (Moher 1996) and
summarised as follows:
1. Was the study described as randomised (1 = yes; 0 = no)?
2.Was the study described as being double blind (1 = yes; 0 = no)?
3. Was there a description of withdrawals and dropouts (1 = yes;
0 = no)?
4. Was the method of randomisation well described and appropri-
ate (1 = yes; 0 = no)?
5. Was the method of double blinding well described and appro-
priate (1 = yes; 0 = no)?
6. Deduct 1 point if methods for randomisation or blinding were
inappropriate.
Inter-rater reliability was measured using simple agreement, kappa
and weighted kappa statistics.
In addition it was noted, if stated in the published results, whether
the study outcomes were assessed by a person who was blinded to
the treatment allocation.
Analysis
Although other study designs are referred to, only data forRCTs are
analysed in this review. Only dichotomous outcomes were avail-
able for analysis, and were assessed using the following statistical
techniques:
• Odds ratios (OR) were calculated with 95% confidence
intervals using Peto’s methods.
• Event rates are expressed as rate ratios, which is the ratio of
the rate in the intervention group to the rate in the control
group. The rate ratio was subsequently converted into a natural
logarithm before entering into RevMan. A correction of 0.5 was
added to each count where there were cells with zero events. An
approximate standard error of the log rate ratio was calculated
with
√
(1/A + 1/C), where A is the rate for the intervention
group, and C is the rate for the control group.
• Funnel plots which display sample size against effect size
were checked, where possible, to test for publication bias.
We carried out tests for heterogeneity during RevMan analyses. If
the percentage variation not attributable to chance exceeded 30%,
a random-effects analysis was used to determine the impact of be-
tween study variation on the overall pooled estimate. If signifi-
cant heterogeneity existed we performed sensitivity analysis using
study quality as a categorising variable. If the heterogeneity was
not sufficiently accounted for by study quality, we identified the
following sub-group analyses a priori:
1. vaccine type;
2. severity of COPD ( assessed by lung function; mild = FEV1
50 to 79% predicted, moderate = FEV1 35 to 49% predicted and
severe = FEV1 < 35% predicted);
3. setting of study;
4. match between strain of vaccine and infecting strains;
5. age of patients.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Searches conducted in 2003 of the Airways Group COPD trials
register yielded a total of 46 references. However, additional hand
searching of conference proceedings and bibliographies of pub-
lished articles identified a further 27 references that were subse-
quently retrieved. Of the 73 articles, 65 did not meet the inclusion
criteria (review article: N = 25; cohort or case controlled study: N
= 12; inappropriate patient population: N = 3; participants un-
likely to have had COPD: N = 6; retrospective studies of efficacy
or isolates: N = 3; cost benefit or effectiveness analysis: N = 3;
study of antibody response: N = 2; position paper: N = 1; editorial:
N = 1; inappropriate comparison: N = 1; inappropriate randomi-
sation: N = 1; meta-analysis: N = 1; trial of immunization rates:
N = 1; case report: N = 1; survey: N = 1; duplicate publication:
N =1; correspondence: N = 1; commentary: N = 1); six contained
participants with COPD for which no data were available for this
sub-group , and two trials met all criteria and for which data could
be extracted for this review. A further search of the Airways Group
trials register in April 2004 yielded an additional 16 citations of
which 15 failed to meet the inclusion criteria (totally irrelevant: N
= 8; inappropriate intervention: N = 2; inappropriate (oral) vacci-
nation: N = 2; study of antibody response: N = 1; inappropriate
comparison: N = 1; commentary: N = 1). A further search in 2006
produced one further publication of interest.
For full details of exclusions, see Characteristics of excluded
studies.
Included studies
For specific details of each study included in the review, see
Characteristics of included studies.
Two studies required translation into English based upon a stan-
dardised translation pro forma used by the Airways Group: Gaillat
1985 fromFrench, and the pre-published report of Alfageme 2006
from Spanish.
4Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Of the 10 studies identified that includedparticipantswith chronic
lung disease (in 11 citations; Davis 1984 briefly cites preliminary
results of the study published later inDavis 1987), only four studies
could be included in the analyses. The four randomised controlled
trials of pneumococcal vaccines included a total of 937 partici-
pants with outcome data for COPD participants (Alfageme 2006;
Davis 1987; Leech 1987; Steentoft 2006). Two of these studies
used 23-valent pneumococcal vaccines (Alfageme 2006; Steentoft
2006) while the other two studies used 14-valent pneumococcal
vaccines (Davis 1987; Leech 1987). Three of the four trials were
placebo-controlled, while the participants in Alfageme 2006 were
randomised to receive either vaccination or no vaccination and
thus by definition was only single-blind.
The six trials that included persons with chronic lung diseases for
which outcome data were unavailable are Gaillat 1985, Klastersky
1986, Koivula 1997, Ortqvist 1998, Riley 1977 and Simberkoff
1986. All authors responded to our requests for sub-group analyses
for COPD participants, though none were able to provide data.
The six studies were conducted in mainly elderly and/or chroni-
cally ill participants of whom a proportion had chronic lung dis-
ease. Riley 1977 included 11,958 participants in the highlands of
Papua New Guinea, some of which had “chronic lung disease”.
The proportion of persons with lung disease is not stated. Gaillat
1985 reports results on1,686persons living in aged care facilities in
France. The author indicated that it was highly likely that persons
with COPDwere among the studied participants, though no anal-
yses are available for this subgroup. The proportion of personswith
lung disease is not stated. The study by Klastersky 1986 was con-
ducted in 50 persons with bronchogenic carcinoma. The author
mentioned that many of these persons had COPD, though the
original analyses did not stratify by this group. Simberkoff 1986
studied 2,295 high risk individuals from north-eastern USA, and
which included persons with chronic pulmonary diseases (23.4%
of all participants). The single-blinded study by Koivula 1997 was
conducted in 2,837 elderly participants living in Sweden, and in-
cluded participants with “lung disease” (4.5% of all participants).
The trial by Ortqvist 1998 studied 691 non-immunocompro-
mised participants aged 50 to 85 years from Sweden, of whom
21.7% had self-reported chronic pulmonary disease.
It is worthwhile noting why one particular study (Halasa 2001,
written in the Polish language) was not included in this review. It is
a double blind, placebo controlled trial with 24 patients who had
non-atopic infectious asthma andCOPD. Phase 1 of the trial was a
parallel study, with phase 2 being a cross-over study. Although the
placebo used a saline injection, the reason for exclusion was that
the intervention used an injectable auto vaccine prepared from
pathogenic and physiological bacterial strains. The study protocols
strictly limited the injectable vaccine to a standardised dose of
either 14- or 23-valent pneumococcal antigen.
The following descriptions refer only to the four studies whichmet
the inclusion criteria for this review. Further details are available
in the table for ’Characteristics of included studies’.
Study setting and design
All studies were conducted in a community setting.
All four studies were randomised, parallel group trials. Davis 1987
allocated participants to treatment groups using random number
tables. Steentoft 2006 used block randomisation to assign par-
ticipants to either one of three treatment groups or to the con-
trol group, and is not described as a double-blind study. Alfageme
2006 assigned participants in blocks of 10 per group by means of
a random number generator. Leech 1987 does not describe the
randomisation methods. Blinding was briefly described for Davis
1987, Leech 1987, and Steentoft 2006 clearly describes its method
of allocation concealment.
Patient population
The common inclusion criterion for each of the four studies was
for participants to have COPD, and the common exclusion crite-
ria was previous pneumococcal vaccination. Davis 1987 included
103 COPD participants with disease status determined by clin-
ical and pulmonary function criteria (not further defined). The
average FEV1 in the active group was 1.33 L. Participants were
followed for 24 to 32 months. Leech 1987 recruited 189 partici-
pants with COPD (FEV1 < 1.5 L) diagnosed by a physician. The
average FEV1 for the active group was 0.94 L. Participants were
followed for a total of two years. The subjective nature of the di-
agnoses made in both of these studies, together with the absence
of reversibility testing, does not exclude the possibility that study
samples were contaminated with asthmatic participants. For de-
tails of lung function parameters at baseline in both studies please
see “Characteristics of included studies”. Alfageme 2006 recruited
600 participants with a loss of four to follow up. Of those in the
active group, 44% of experimental participants had an FEV1 <
40% expected (38% in the control group). Thirty females were
included in the study. The study by Steentoft 2006 included a total
of 49 participants (27 male) and was primarily aimed at assessing
the efficacy of pneumococcal vaccination with a co-intervention
of steroid treatment. Participants were assigned to one of three in-
tervention groups that differed according to the timing, duration
and dose of systemic steroid treatment. The control group was
not given a vaccine, and it is assumed that it also did not receive
any steroid treatment. COPDwas diagnosed according to GOLD
criteria.
Age: The average age of participants was similar in all studies (mid
to high 60’s).
Tobacco smoking status: Davis 1987 describes 53% as current
smokers in the vaccine group versus 33% in placebo, with five
never smokers in each group. In Alfageme 2006, there were 65
current smokers in the vaccine group and 77 in the control group.
Steentoft 2006 describes 46% of the participants in the interven-
tion groups (n = 37) and 58% of the controls (n = 12) as being
current smokers with the rest being previous smokers.
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Co morbidities: Davis 1987 indicates that the number of patients
were similar in both groups for cardiovascular disease, diabetes, and
history of excessive alcohol consumption. Alfageme 2006 shows
no difference between groups in terms of previous pneumonia
or tuberculosis. There was also no between-group difference in
detection of neoplasia during follow-up. Steentoft 2006 and Leech
1987 do not report comorbid conditions.
Drop-outs: For Leech 1987, 23 persons in total were lost to follow
up (group allocation not reported); Alfageme 2006, two persons
from each group lost to follow up; dropouts in Davis 1987 and
Steentoft 2006 were not explicitly stated, giving the appearance
that there were none.
Intervention
Davis 1987 and Leech 1987 used injectable vaccines of 14-valent
pneumococcal capsular antigens in the active groups, with ster-
ile physiologic saline placebo for the control groups. Davis 1987
injected a standard dose of the 14 valent pneumococcal capsular
antigens (0.5 ml containing 50 mcg of each of the 14 capsular
antigens, totaling 700 mcg) . The dose was not stated for Leech
1987, though it is assumed to be the same as that given in Davis
1987. Steentoft 2006 and Alfageme 2006 used 0.5ml of 23-valent
pneumococcal vaccines for the treatment groups (containing 25
mcg of each antigen totaling 575 mcg). In both of these studies,
the vaccine was withheld from the control groups instead of the
administration of a placebo and are therefore single-blind studies
by definition. Injections in all studies were given subcutaneously.
Participants were followed up for 48 months post-vaccination
in Davis 1987 , 24 months in Leech 1987 and six months for
Steentoft 2006. The median study duration for Alfageme 2006
was approximately 980 days.
Outcomes
Available outcome data are summarised in the ’Additional Tables’.
All studies except Steentoft 2006 provided mortality data. The
incidence of pneumonia was available fromDavis 1987, Alfageme
2006, and Steentoft 2006. In addition, Davis 1987 and Leech
1987 measured antibody titers. As this review is concerned with
clinical rather than biological outcomes, these data were not ex-
tracted. Leech 1987 also recorded emergency visits, admission to
hospital, length of hospital stay and adverse events. No data are
available for length of stay and adverse events.
Risk of bias in included studies
For the four studies in the review, quality was assessed using two
methods:
1. Adequacy of concealment
Based on the published articles, it was possible to establish the
method of allocation concealment for only one of the four stud-
ies (Steentoft 2006). This study was given an A grade while the
reaminating studies received a B. The trialists were not contacted
for more details on this particular issue.
2. Jadad Score
One study had a score of 4/5 (Davis 1987), two studies 3/5 (Leech
1987, Alfageme 2006) and one with a score of 2/5 (Steentoft
2006).
Effects of interventions
After extensive electronic and handsearching, we located 11 ci-
tations (reporting 10 studies) that met the inclusion criteria. Of
these 10 studies, only four were conducted on participants where
COPD was an inclusion criterion for study participation. In these
four studies, there was a total of 937 case-available participants.
The other six papers reported trials of elderly and /or chronically
ill patients of whom a subset had chronic lung disease, but for
which no data was available to include in this review. With one
exception, data is displayed in the tables of comparisons by the
number of capsular polysaccharide antigens used in the vaccine
(greater than 14 versus 14 or less). The exception is for the pneu-
monia outcome, where provision is made for stratifying results
according to baseline lung function. No data was available for 4
of the 8 proposed outcomes: days of disability; change in lung
function; adverse effects of treatment; and cost of pneumococcal
vaccination.
Only dichotomous data are reported, as no continuous data for
the outcomes of interest were available. The generic inverse vari-
ance methodology was used for determining rate ratios for inter-
vention and control groups for two outcomes (hospital admissions
and emergency department visits). Ninety five percent confidence
intervals (95% CI) were applied to fixed odds ratios (OR) and
fixed rate ratios (RR). No meta-analyses included data that were
derived from all four studies.
Primary outcome
Acute exacerbations
Only Steentoft 2006 provided data for participants who experi-
enced acute exacerbations of COPD. There was no significant dif-
ference between vaccination and placebo for this outcome, OR
1.43 (95% CI 0.31 to 6.69). Leech 1987 provided hospital ad-
mission rates due to acute exacerbations (rate ratio 0.83), but this
also found no significant difference between interventions.
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Secondary outcomes
Pneumonia
Davis 1987, Alfageme 2006, and Steentoft 2006 reported data
for participants suffering one or more episodes of pneumonia.
Overall, there was no significant difference between intervention
and control groups, odds ratio 0.89 (95% CI 0.58 to 1.37). Only
Alfageme 2006 reported results byCOPD severity: vaccinated per-
sons with FEV1 < 40% predicted at baseline had an odds of con-
tracting pneumonia of 0.47 (95% CI 0.22 to 1.01) compared to
control participants, whereas vaccinated participants with a FEV1
≥ 40% predicted had an odds ratio of 1.12 (95% CI 0.5 to 2.49)
compared to control. Leech 1987 provided rates of hospital ad-
missions and emergency visits due to pneumonia (rate ratio 1.98
and 0.99 respectively, neither reaching statistical significance).
Hospital admissions
Leech 1987 and Steentoft 2006 reported details of hospitalisation,
but it was not possible to combine the data in a meta-analysis.
Leech 1987 reported rates of hospital admissions for pneumonia
(rate ratio 1.98, 95%CI 0.66 to 5.91), for acute exacerbations
(rate ratio 0.83, 95% CI 0.54 to 1.27), and for all causes (rate
ratio 1.01, 95%CI 0.72 to 1.41), none of which were significantly
different between intervention and control groups. Steentoft 2006
reported the actual numbers of participants admitted to hospital
for the three intervention and single control groups. Once again
no significant difference was found between interventions (OR
0.95, 95% CI 0.26 to 3.48).
Emergency department visits
Only Leech 1987 reported results for emergency department vis-
its. As for hospital admissions, no significant difference between
vaccination and control groups was found for emergency visits due
to pneumonia (rate ratio 0.99; 95% CI 0.52 to 1.88), lower respi-
ratory tract infections (rate ratio 1.00, 95% CI 0.75 to 1.33), or
upper respiratory tract infection (rate ratio 1.29, 95% CI 0.68 to
2.47). There was no significant difference between interventions
for all-cause visits to the emergency department, rate ratio 1.15
(95% CI 0.68 to 2.47).
Mortality
Three studies (Davis 1987; Leech 1987; Alfageme 2006) that in-
cluded 888 participants provided data for death from all causes.
There was no significant difference between interventions for all
cause mortality, OR 0.94 (95% CI 0.67 to 1.33), or death from
cardiorespiratory causes, OR 1.07 (95% CI 0.69 to 1.66).
With respect to mortality, the follow-up period for each of these
three studies differed. Davis and Alfageme followed participants
up to 48months, while Leech followedparticipants for 24months.
None reported mortality statistics for the first 12 months only.
Other secondary outcomes
None of the studies reported data for disability, change in lung
function, adverse effects nor costs associated with pneumococcal
vaccination. However, Leech stated “There were no adverse reac-
tions to pneumococcal vaccine” and Alfageme indicated that “no
patient reported any local or systemic reaction to the vaccine”.
Davis 1987 and Steentoft 2006 do not make any specific refer-
ence to adverse effects, although Davis states that participants had
a “normal response to the vaccine”, which is believed to refer to
antibody responses.
D I S C U S S I O N
In this systematic review,we have included fourRCTswhich report
the effects of injectable pneumococcal vaccination in persons with
COPD. There were no statistically significant findings from this
review to indicate whether pneumococcal vaccination provides
protection against acute exacerbations or pneumonia in persons
with COPD.
Unfortunately the outcomes reported in the studies allowed few to
be combined in any of the meta-analyses we performed. Rates of
hospital admissions and emergency department visits were derived
from only one study (Leech 1987). The methodological quality of
this study involving 189 participants was acceptable, but failed to
show any difference in rates between the two interventions. The
inability to detect a difference may have been due to a combina-
tion of small sample size, and a low frequency of pneumococcal
infection. The authors performed a power calculation which sug-
gested that at least 500 participants in each group would have been
required to show a statistically-significant risk reduction of 40%
for pneumococcal infection. In addition, the authors also suggest
that the low infection rates in this population may have been due
to naturally-acquired antibodies from prior infections, effectively
diminishing the apparent efficacy of the vaccine.
Davis 1987 also had a small number of participants withCOPD in
the trial (n = 103). Of interest is the prevalence of pre-vaccination
isolation of pneumococcus from sputum (active = 9%; placebo
= 13%) compared to post-vaccination isolation (active = 13%;
placebo = 7%). The placebo group in this study had an estimated
post-intervention rate of pneumonia of 49/1000 pt-yrs, versus
30.3/1000 pt-yrs in the active group. Interpretation of these results
is confounded by the difference between the two groups for rates
of pneumococcal pneumonia prior to the study (placebo = 22.9/
1000 pt-yrs, active 13.8/1000 pt-yrs) and any pneumonia (placebo
= 57/1000 pt-yrs, active 35/1000 pt-yrs).
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The largest study is by Alfageme 2006, though it does not appear
to have the same methodological rigour as that of the others. The
study was initially identified in a hand-search of abstracts from
conference proceedings, with preliminary results obtained from
direct contact with the authors. The full results of the study were
formally published in 2006. It could be argued that since the
single-blind study design failed to include a placebo comparison,
it is inappropriate for inclusion in this review. It is nonetheless
a randomised trial where one group of patients were allocated
to receive the 23-valent vaccine, and the other (control) group
allocated to receive no intervention. Even with the limitations
inherent with this study design, the results are in keeping with the
other trials of injectable vaccines. If gender is thought tomodify the
biological activity of the vaccine, the generalisability of the results
may be limited since only 5% of the participants were female. As
cigarette smoking is widely recognized as the single biggest risk
factor in the development of COPD, the imbalance of gender in
this study may simply be a reflection of the imbalance of male
and female smokers in the country where the study was conducted
(Spain). Across all studies, there were insufficient data to stratify
results by gender.
Steentoft 2006 was the smallest of the four studies (n = 49), and
interpretation of the results are complicated by the fact that there
was a co-intervention requiring participants to be placed into one
of three steroid treatment groups (n = 13, 9, 15) or a control group.
It appears that the researchers in this study were particularly inter-
ested, as were those in Leech 1987 and Davis 1987, in biological
outcomes such as antibody levels.
Disappointingly, analysis by severity of COPD was possible for
only one study (Alfageme 2006). In addition, no studies provided
data for side effects of the vaccination under investigation, other
than stating that the vaccines were well tolerated.
There were a further six RCTs that could have contributed data
for this review if sub-group analyses had been available for the
participants with COPD. In the study by Klastersky 1986, all
participants were admitted with bronchogenic carcinoma and it
is likely some of these would have had coexistent COPD. Most
other studies excluded persons with malignancies. There were no
differences in clinical outcomes (11.5% in the vaccine group ver-
sus 19% in the placebo developed pneumococcal infections) be-
tween the interventions. The study by Gaillat 1985 undertaken
among residents living in aged-care facilities favoured vaccination
with respect to pneumonia, though there was no reduction in risk
of mortality. In the single-blind study of elderly participants by
Koivula 1997, the overall results showed no reduction in events of
pneumonia between interventions. A sub-group analysis showed
a protective effect of pneumococcal vaccination in those persons
at increased risk of pneumonia (age ≥ 70 years, heart disease,
lung disease, bronchial asthma, alcoholism, institutionalised, or
permanently bedridden). The protective efficacy, defined as 100
x (1-odds ratio of having been vaccinated), was 59% (95% CI 6
to 82%) in this increased risk sub-group This finding is not in
keeping with that of Simberkoff 1986, who conducted a study
in 2295 high-risk patients aged > 50 years and found no differ-
ence in events of pneumonia or bronchitis. Persons at high risk
of pneumonia in this population were defined by having one or
more of the following risk factors: age > 55, chronic renal, hepatic,
cardiac or pulmonary diseases, alcoholism, or diabetes mellitus.
The study by Riley 1977 in 11,958 persons in the highlands of
Papua NewGuinea showed a reduction in deaths from respiratory
causes, though the vaccine had little efficacy in protecting against
lower respiratory tract infections. The trial by Ortqvist 1998 in
persons aged 50 to 85 years was unable to show a reduction in risk
of pneumonia, pneumococcal pneumonia, and mortality for the
vaccine group compared to those receiving a saline placebo.
Studies using a retrospective, case-control design have found that
pneumococcal vaccination has an efficacy of approximately 50 to
80% against invasive pneumococcal disease in high risk popu-
lations (Fedson 1994; Leophonte 2001). The data derived from
such studies often included persons with chronic lung conditions,
though analyses were not limited to persons with only COPD.
Prospective cohort studies have generally failed to show reduc-
tions in the risk of non-bacteraemic infections, though protec-
tion against bacteraemia has been demonstrated (Jackson 2003).
An indirect cohort study conducted by the Centers for Disease
Control and Prevention documented an efficacy of 65% (95% CI
26% to 83%) in persons with chronic pulmonary diseases (Butler
1993). This study utilised cases of pneumococcal infection, and
compared the distribution of pneumococcal serotypes causing in-
fection in those whowere vaccinated and unvaccinated. Regardless
of design, most studies have found that the protective efficacy of
vaccination is uniformly diminished in the elderly and immuno-
compromised.
Pneumococcal vaccination in COPD is generally advocated in
clinical guidelines by the internationally-recognised thoracic so-
cieties. The American Thoracic Society together with the Euro-
pean Respiratory Society released guidelines in June 2004, stat-
ing that “vaccination against pneumococcal disease reduces bac-
teraemia in vaccinated patients with pneumonia. The vaccination
is indicated for all elderly patients depending on national recom-
mendations” (ATS 2004). Guidelines from the UK’s National In-
stitute of Clinical Excellence (NICE) state that “pneumococcal
vaccination and an annual influenza vaccination should be offered
to all patients with COPD as recommended by the Chief Medical
Officer” (NICE 2004). The COPDX guidelines for Australia and
New Zealand state that “pneumococcal vaccination (polyvalent
covering 23 virulent serotypes) is recommended in this group. The
vaccination should be repeated five-yearly. There is no evidence or
rationale for vaccinating more frequently in COPD” (McKenzie
2003). There is less enthusiasm for such a recommendation by the
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
guidelines published jointly by the USA’s National Heart Lung
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Blood Institute and the World Health Organization. This guide-
line suggests that “pneumococcal vaccine containing 23 virulent
serotypes has been used but sufficient data to support its general
use in COPD patients are lacking” (NHLBI 2001). Our find-
ings from the available RCT evidence is that injectable polyvalent
vaccines have not been shown to provide significant protection
against morbidity and mortality in persons with COPD.
Methodological limitations
The total number of participants that contributed data to this re-
view was 937 participants. Given the small number of trials and
few participants, it is not possible to exclude the possibility that
vaccination is efficacious for the outcomes investigated. As Fedson
et al indicate in their commentary (Fedson 1994), it is possible
that one reason clinical trials have failed to show a benefit from
pneumococcal vaccination is an overestimation of the incidence
of pneumococcal infections in the study population, rather than
a lack of vaccine efficacy per se. Another possibility is the small
participant numbers for most outcomes; as Leech 1987 suggested,
participant numbers close to 1000 would be needed to demon-
strate whether some findings from individual studies are indeed
statistically significant. We were able to include numbers of this
magnitude for a minority of our outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The limited evidence from RCTs included in this review of per-
sons with COPD found no significant difference for morbidity or
mortality between those injected with pneumococcal vaccination
and those who served as controls.
Implications for research
The evidence of efficacy for pneumococcal vaccination in COPD
is derived from RCT level evidence, which is conflicting. Such
evidence is limited by few randomized trials, small sample size,
utilisation of post hoc or sub-group analyses,and inconsistent re-
sults. The recommendations in clinical practice guidelines may
have been based largely on evidence in participants different to
the target population (persons with COPD). What is needed to
confirm efficacy of pneumococcal vaccination in COPD are large,
adequately powered randomised placebo-controlled trials using
participants with COPD.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alfageme 2006
Methods Setting of study: Population-based intervention
Study design: RCT parallel
Jadad scoring system:
-Described as randomized? Yes
-Described as double blind? No
-Described withdrawals/dropouts? Yes
-Randomization described, appropriate? Yes
-Blinding described, / appropriate? No
-Random / blinding method inappropriate? No indication
Total Score = 3
Study outcomes assessed by person blinded to Tx allocation? Yes
Type of analysis: Case available
Participants Total number of participants: 600 (4 lost to follow up; 2 from each group)
Gender distribution: vaccine group M = 96.6%; control group M = 93.3%
Mean age: vaccine group = 69; control group = 68 Age range: vaccine group = 62-73; control group = 61-
73
Inclusion criteria: COPD
Exclusion criteria: Prior pneumococcal vaccination, pregnant, immunosuppressed, known neoplasia, renal
insufficiency in dialysis, HIV infection, hypogammaglobulinaemia, anatomical and/or functional asplenia
Diagnostic criteria (COPD): SEPAR criteria (Sociedad Espanola de patologia respiratoria, or Spanish
Society of Respiratory Pathology), FEV1< 80% and FEV1/FVC < 70%
Severity of COPD: vaccine group for FEV1 < 40% = 132; >= 40% = 166; control group for FEV1 < 40%
= 114; >= 40% = 184
Current smokers: vaccine group = 22%; control group = 26%
Diagnostic criteria (pneumonia): Clinical symptoms (lower respiratory tract infection with fever) and
imaging findings (new infiltrate typical of pneumonia which decreases during follow-up). Pneumococcal
pneumonia diagnosed with isolated S pneumoniae in blood, pleural fluid or bronchial samples.
Microbiological diagnosis (pneumococcus): presence of pneumonia and the isolation of S pneumoniae
from sputum, bronchoaspirate, blood, pleural fluid, or CSF
Interventions Vaccine type: 23 valent pneumococcal capsular polysaccharide
Numbers in each group: Intervention = 298; No intervention = 298
Dose: 0.5ml Pneumo23, Sanofi-Pasteur MSD
Delivery: subcutaneous injection in deltoid muscle
Co-interventions: None
Comparison: No vaccine
Duration of study: vaccine group, median of 980 days (range 20-1454); control group, median of 978
days (range 21-1183)
Outcomes Types of outcomes measured:
Acute exacerbations (Yes) C = 9; I = 30
Pneumonia (Yes) C = 5; I = 11
Days of disability (No)
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Alfageme 2006 (Continued)
Number of hospital admissions (Yes, call causes) C = 6; I = 18
Change in lung function (Reported, but cannot use data)
All cause mortality in yr post vac. (No)
Adverse effects of treatment (No)
Cost of vaccination (No)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
Davis 1987
Methods Randomised, double-blind, placebo controlled trial.
Method of randomisation: Random number table. participants studied for 1-48 months of treatment
Jadad scoring system:
-Described as randomized? Yes
-Described as double blind? Yes
-Described withdrawals/dropouts? No
-Randomization described, appropriate? Yes
-Blinding described, / appropriate? Yes
-Random / blinding method inappropriate? No
Total Score = 4
Study outcomes assessed by person blinded to Tx allocation? Yes
Participants Total number of participants: 103
Gender distribution: Not stated
Mean age: Intervention 64 ± 10 Control 61 ± 10
Age range: Not stated
Inclusion criteria: COPD (assessed by clinical and pulmonary function criteria)
Exclusion criteria:
1. reversible airflow obstruction in the absence of chronic bronchitis (cough 3 of 12 months, and for 3
consecutive years) or emphysema as judged clinically, radiologically, and by lung function testing.
2. malignant neoplasms
3. sickle cell disease
4.severe renal impairment
5.severe hepatic impairment
Diagnostic criteria (COPD):ATS standards
Severity of COPD: Active: FEV1 (L)= 1.33±0.61; FEV1/FVC=52±13 Placebo: FEV1 (L)= 1.47±0.75;
FEV1/FVC=55±14
Smoking Status: Active: current=53%, never n=5; Placebo: current=33%, never n=5
Diagnostic criteria (pneumonia): Clinical and imaging findings in the presence of pneumococcus in
sputum
Etiological diagnosis (pneumococcus): Diagnosis only if pathogens isolated from blood or body fluids.
Processed <6hr after collection.
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Davis 1987 (Continued)
Microbiological methods described.
Baseline characteristics (smokking status):
Current smokers: PLA: 27/53; VAX: 17/50 (p=0.036 for difference); Non-smokers: PLA: 5; VAX: 5
Interventions Vaccine type: 14 pneumococcal capsular polysaccharide antigens
Numbers in each group: Intervention = 50 Placebo = 53
Dose: 0.5ml (50 mcg of each of the 14 capsular antigens)
Delivery: Subcutaneous injection
Co-interventions: None
Comparison: Saline
Duration of study: 24-32 months
Patients followed up for 48 months (mean follow up in each arm: PLA: 32.2 months; VAX: 31.7 months)
Outcomes Anitbody titers; flora of sputum; incidence of pneumonia; mortality
Acute exacerbations (Yes)
Days of disability (No)
Number of hospital admissions (No)
Change in lung function (No)
All cause mortality in yr post vac. (Yes)
Adverse effects of treatment (No)
Cost of vaccination (No)
Comments on outcomes: Mortality cases from 1-48 months after vaccine
The rate of episodes/1000 patient years for prior pneumonia: Active = 35, Placebo = 57
The rate of episodes/1000 patient years for prior pneumococcal pneumonia: Active = 13.8, Placebo = 22.
9
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
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Leech 1987
Methods Randomised, double-blind, placebo controlled trial. Method of randomisation: Not reported. Patients
stratified by age and FEV1. Setting: Montreal Chest Hospital (stable ambulatory population). With-
drawals: 23 participants could not be traced for follow-up and were excluded from analysis of death rates
Jadad scoring system:
-Described as randomized? Yes
-Described as double blind? Yes
-Described withdrawals/dropouts? No
-Randomization described, appropriate? No
-Blinding described, / appropriate? Yes
-Random / blinding method inappropriate?
Total Score=3
Type of analysis: Case available
Participants Total number of participants: 189
Gender distribution: Vaccine (M) = 66 Placebo (M) = 69
Mean age of patients: Vaccine=66 ± 9 Placebo = 67 ± 9
Age range: 40-89
Inclusion criteria for active group: Patients seen in the outpatient clinic who had COPD (FEV1< 1.5L)
Exclusion criteria:Previous pneumococcal vaccination, asthma, cystic fibrosis or bronchiectasis
Diagnostic criteria (COPD): Not stated, other than a prior diagnosis of COPD by their own physician
Severity of COPD: Vaccine group (mean) FEV1=0.94L FVC=2.18L/s; Placebo group (mean) FEV1=0.
96L FVC= 2.13L/s
Diagnostic criteria (pneumococcal pneumonia): Pneumonia defined as patient having symptoms of lower
respiratory tract infection (fever, increased cough, and a change in colour or an increase in the quantity
of sputum) and evidence of new infiltrate on chest X-ray.
Microbiological diagnosis (pneumococcus): Not stated, though sputum cultured in 10% of subjects
N = 189. (VAX: 92; PLA: 97). Gender: PLA: M: 69; VAX: 66; Mean age: PLA: 67 (SD 9); VAX: 66 (SD
9); FEV1 (L): PLA: 0.96 (SD 0.30); VAX: 0.94 (SD 0.26); FVC: PLA: 2.13 (SD 0.64); VAX: 2.18 (SD
0.58)
Interventions Vaccine types:14 valent pneumococcal polysaccharide (in one arm) and influenza vaccination (in the other
arm)
Numbers in each group: Intervention = 92 Placebo = 97
Dose: not stated
Delivery: Injection
Co-interventions: none
Comparison: Saline (in one arm) and influenza vaccination (in the other arm)
Follow-up points: 6-month intervals
Duration of study: 2 years
Influenza vaccination (given at baseline, end of years 1 and 2…unless previous adverse reaction or declined)
Outcomes Incidence of pneumonia; mortality (all cause); admission to hospital (all cause); length of hospital stay;
Emergency visits (all causes); adverse events (pneumococcal sepsis)
Notes
Risk of bias
Item Authors’ judgement Description
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Leech 1987 (Continued)
Allocation concealment? Unclear Information not available
Steentoft 2006
Methods Setting of study:
Hospital-based
Study design:
RCT parallel: 1 control group with three levels of steroid load, block randomized to vaccine or no vaccine
Allocation concealment:
A (clear)
Jadad scoring system:
Described as randomized? Yes
Described as double blind? No
Described withdrawals/dropouts? No
Randomization described, appropriate? Yes
Blinding described, / appropriate? No
Random / blinding method inappropriate? No
Total Score = 2
Study outcomes assessed by person blinded to Tx allocation?
Not stated for clinical diagnoses. Laboratory staff assessing antibody levels were blinded to allocation
Type of analysis:
Case available
Participants Total number of participants:
49
Gender distribution:
M = 27; F = 22
Mean age:
Control: 67.5 years
Intervention: 65, 72 and 71 years for the three groups
Age range:
47-86 years
Inclusion criteria:
COPD
Exclusion criteria:
Prior pneumococcal vaccine (implied)
Diagnostic criteria (COPD):
COPD defined by GOLD guidelines (FEV1/FVC<70%, FEV1 reversibility-test<200ml)
Severity of COPD at baseline:
Control: FEV1%=50.2
Intervention: FEV1%= 48.2, 46.0, and 44.2 for the three groups
Smoking Status:
Active: current=46%, past=54%
Placebo: current=58%, past=42%
Diagnostic criteria (pneumonia):
Radiologically verified, though no other criteria stated
Etiological diagnosis (pneumococcus):
Not described
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Steentoft 2006 (Continued)
Interventions Vaccine type:
23 polyvalent pneumococcal vaccine
Numbers in each group:
Intervention = 37
Placebo = 12
Dose:
0.5ml
Delivery:
Subcutaneous injection
Co-interventions:
Three groups with various exposure patterns to oral prednisolone
* no steroid 3 months before vaccination, then steroids for 4 weeks after vaccination
* chronic steroid treatment, before and after vaccination
* vaccination after 4 weeks with steroid treatment, then no steroids after vaccination.
Groups 1 and 3 above received 37.5mg starting dose of prednisolone, tapered to 0 during the respective
time frames
Comparison:
No vaccine
Duration of study:
6 months
Outcomes Types of outcomes measured:
Acute exacerbations (Yes) C = 9; I = 30
Pneumonia (Yes)C = 5; I = 11
Days of disability (No)C = 6; I = 18
Number of hospital admissions (Yes, though reasons for admissions not given)
Change in lung function (Reported, but cannot use data)
All cause mortality in yr post vac. (No)
Adverse effects of treatment (No)
Cost of vaccination (No)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Third party randomisation
COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory volume in 1 second; MSD:Merck Sharpe and Dohme; PLA:
Placebo; Tx: Treatment; VAX: vaccination
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aboussouan 1996 Review article
Anonymous 1999 Position paper
Anonymous 1999b Review article
Austrian 1976 Participants are unlikely to have had COPD, and certainly
no results are available for COPD persons.
Austrian 1981 Review article
Austrian 1984 Editorial
Bacle 1997 Review article
Bentley 1981 Review article
Bolan 1986 Comparison of serotypes
Broome 1981 Review article
Butler 1992 Retrospective analysis of vaccine efficacy
Butler 1993 Retrospective analysis of vaccine efficacy
Chodosh 1991 Review article
Christenson 2001 Prospective study (not RCT)
Davis 1984 Preliminary results of the paper published in 1987
Douglas 1979 Review article
Douglas 1984 Study carried out in children 6-54 months
Ekwurzel 1938 Excluded because of young patients, which are unlikely to have had COPD (“youthful group, 80% being under
25 years of age”)
Ewig 1999 Review article
Farr 1995 Matched case-controlled study
Fedson 1989 Review article
Fedson 1994 Review article
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(Continued)
Fedson 1999 Review article
Felton 1938 Cohort observation study
Ferguson 1993 Review article
Filice 1990 Review article
Fine 1994 Meta-analysis
Forrester 1987 Case control study
Foschino 1995 Oral immunomodulator (not injectable vaccine)
Gable 1990 Retrospective cohort study
Gaillat 1985 No data were available for COPD patients
Gardner 1993 Review article
Hak 1998 Prospective cohort study
Halasa 2001 Injectable vaccine includes antigen from pneumococcus and other bacteria (in Polish language)
Hilleman 1981 Review article
Hirschmann 1981 Review article
Hirschmann 1994 Commentary
Horwood 2002 Review
Jackson 2003 Retrospective cohort study
Jonsson 2002 This is not a placebo controlled RCT. The trial compares a 23 valent pneumococcal vaccine with a type 6B
polysaccharide conjugated to tetanus toxoid
Kaiser 1974 Retrospective analysis of isolates
Kaufman 1941 Participants not adequately randomised. Participants allocated to active treatment by volunteering in one year
and by alternate allocation in the subsequent year
Kaufman 1947 Likely to have included COPD participants given the age range of those involved in the study (80% > 60
years), though inclusion of persons with COPD was not explicitly stated. Contact has been made with the
originating institutions to obtain relevant analyses of this subgroup, though it is improbable that any results
will be available due to the age of the publication
Klastersky 1986 No data were available for COPD patients
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(Continued)
Klein 1983 Trial of immunization rates
Koivula 1997 No data were available for COPD patients
Kraus 1985 Study of antibody responses
LaForce 1989 Review article
Landesman 1983 Study of antibody responses
Larsson 1998 Review article
Leophonte 2001 Review article
MacLeod 1945 CCT in young adults; COPD unlikely
Madison 1998 Review article
Monso 2003 Commentary
Nichol 1999 Retrospective cohort control study
Orcel 1994 Oral immunomodulator (not injectable vaccine)
Ortqvist 1998 No data were available for COPD patients
Patrick 1981 Cost benefit analysis
Preheim 1978 Case report
Riley 1977 No data were available for the chronic pulmonary disease patients
Rochemaure 1988 The antigens for this oral immunomodulator are taken from Klebsiella pneumoniae and Escherichia coli (not
Streptococcus pneumoniae)
Saag 1998 Survey
Schwartz 1982 Review article
Shapiro 1984 Case-controlled study
Shapiro 1987 Correspondence
Shapiro 1991 Case control study
Sheikh 1999 Asthma study
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(Continued)
Simberkoff 1986 No data were available for COPD patients
Simberkoff 1993 Review article
Sims 1988 Case-controlled study
Sisk 1986 Cost-benefit analysis, no data on efficacy
Smit 1977 Participants are young adult novice miners, with no indication of chronic lung disease. Wrote to authors for
further information, but received no response as of Oct 2004
van Ampting 1998 Retrospective study of patients hospitalised with infection
Wencker 1999 Alpha 1 antitrypsin deficiency
Wenzel 1976 Inappropriate intervention using mycoplasma rather than streptococcus pneumoniae
Wiebel 1977 Antibody response study
Willems 1980 Non-randomised cost-effectiveness study
Williams 1986 Review article
Wright 1914 Participants are young (otherwise healthy) mining labourers without any indication of having COPD
COPD: Chronic obstructive pulmonary disease; CCT: case controlled trial; RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Pneumococcal vaccine versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Acute exacerbations 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Vaccine >14 serotypes 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 Vaccine 14 or less
serotypes
0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Pneumonia 3 748 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.58, 1.37]
2.1 Vaccine >14 serotypes 2 645 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.61, 1.53]
2.2 Vaccine 14 or less
serotypes
1 103 Odds Ratio (M-H, Fixed, 95% CI) 0.42 [0.10, 1.72]
3 Pneumonia by lung function at
baseline
1 596 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.41, 1.22]
3.1 FEV1<40% expected 1 246 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.22, 1.01]
3.2 FEV1>=40% expected 1 350 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.50, 2.49]
4 Hospital admissions
(exacerbation of COPD)
1 Rate Ratio (Fixed, 95% CI) Totals not selected
4.1 Vaccine >14 serotypes 0 Rate Ratio (Fixed, 95% CI) Not estimable
4.2 Vaccine 14 or less
serotypes
1 Rate Ratio (Fixed, 95% CI) Not estimable
5 Patients admitted to hospital
(any cause)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Vaccine >14 serotypes 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Vaccine 14 or less
serotypes
0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
6 Hospital admissions
(pneumonia)
1 Rate Ratio (Fixed, 95% CI) Totals not selected
6.1 Vaccine >14 serotypes 0 Rate Ratio (Fixed, 95% CI) Not estimable
6.2 Vaccine 14 or less
serotypes
1 Rate Ratio (Fixed, 95% CI) Not estimable
7 Hospital admissions (all causes) 1 Rate Ratio (Fixed, 95% CI) Totals not selected
7.1 Vaccine >14 serotypes 0 Rate Ratio (Fixed, 95% CI) Not estimable
7.2 Vaccine 14 or less
serotypes
1 Rate Ratio (Fixed, 95% CI) Not estimable
8 Emergency visits (upper
respiratory tract infection)
1 Rate Ratio (Fixed, 95% CI) Totals not selected
8.1 Vaccine >14 serotypes 0 Rate Ratio (Fixed, 95% CI) Not estimable
8.2 Vaccine 14 or less
serotypes
1 Rate Ratio (Fixed, 95% CI) Not estimable
9 Emergency visits (pneumonia) 1 Rate Ratio (Fixed, 95% CI) Totals not selected
9.1 Vaccine >14 serotypes 0 Rate Ratio (Fixed, 95% CI) Not estimable
9.2 Vaccine 14 or less
serotypes
1 Rate Ratio (Fixed, 95% CI) Not estimable
10 Emergency visits (lower
respiratory tract infection)
1 Rate Ratio (Fixed, 95% CI) Totals not selected
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10.1 Vaccine >14 serotypes 0 Rate Ratio (Fixed, 95% CI) Not estimable
10.2 Vaccine 14 or less
serotypes
1 Rate Ratio (Fixed, 95% CI) Not estimable
11 Emergency visits (any cause) 1 Rate Ratio (Fixed, 95% CI) Totals not selected
11.1 Vaccine >14 serotypes 0 Rate Ratio (Fixed, 95% CI) Not estimable
11.2 Vaccine 14 or less
serotypes
1 Rate Ratio (Fixed, 95% CI) Not estimable
12 Death from cardio-respiratory
causes, 6-48 months post
vaccine
3 888 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.69, 1.66]
12.1 Vaccine >14 serotypes 1 596 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.66, 1.88]
12.2 Vaccine 14 or less
serotypes
2 292 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.44, 2.18]
13 Death from all causes, 6-48
months post vaccine
3 888 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.67, 1.33]
13.1 Vaccine >14 serotypes 1 596 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.65, 1.47]
13.2 Vaccine 14 or less
serotypes
2 292 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.44, 1.66]
Analysis 1.1. Comparison 1 Pneumococcal vaccine versus control, Outcome 1 Acute exacerbations.
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 1 Acute exacerbations
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaccine >14 serotypes
Steentoft 2006 30/37 9/12 1.43 [ 0.31, 6.69 ]
2 Vaccine 14 or less serotypes
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Pneumococcal vaccine versus control, Outcome 2 Pneumonia.
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 2 Pneumonia
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaccine >14 serotypes
Alfageme 2006 38/298 37/298 73.4 % 1.03 [ 0.64, 1.67 ]
Steentoft 2006 11/37 5/12 12.1 % 0.59 [ 0.15, 2.28 ]
Subtotal (95% CI) 335 310 85.5 % 0.97 [ 0.61, 1.53 ]
Total events: 49 (Pneumococcal Vaccine), 42 (Control)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Vaccine 14 or less serotypes
Davis 1987 3/50 7/53 14.5 % 0.42 [ 0.10, 1.72 ]
Subtotal (95% CI) 50 53 14.5 % 0.42 [ 0.10, 1.72 ]
Total events: 3 (Pneumococcal Vaccine), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Total (95% CI) 385 363 100.0 % 0.89 [ 0.58, 1.37 ]
Total events: 52 (Pneumococcal Vaccine), 49 (Control)
Heterogeneity: Chi2 = 1.80, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.3. Comparison 1 Pneumococcal vaccine versus control, Outcome 3 Pneumonia by lung function
at baseline.
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 3 Pneumonia by lung function at baseline
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 FEV1<40% expected
Alfageme 2006 12/132 20/114 63.2 % 0.47 [ 0.22, 1.01 ]
Subtotal (95% CI) 132 114 63.2 % 0.47 [ 0.22, 1.01 ]
Total events: 12 (Pneumococcal Vaccine), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
2 FEV1>=40% expected
Alfageme 2006 13/166 13/184 36.8 % 1.12 [ 0.50, 2.49 ]
Subtotal (95% CI) 166 184 36.8 % 1.12 [ 0.50, 2.49 ]
Total events: 13 (Pneumococcal Vaccine), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 298 298 100.0 % 0.71 [ 0.41, 1.22 ]
Total events: 25 (Pneumococcal Vaccine), 33 (Control)
Heterogeneity: Chi2 = 2.36, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 1.24 (P = 0.22)
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 1.4. Comparison 1 Pneumococcal vaccine versus control, Outcome 4 Hospital admissions
(exacerbation of COPD).
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 4 Hospital admissions (exacerbation of COPD)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vaccine >14 serotypes
2 Vaccine 14 or less serotypes
Leech 1987 -0.185 (0.2178) 0.83 [ 0.54, 1.27 ]
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
Analysis 1.5. Comparison 1 Pneumococcal vaccine versus control, Outcome 5 Patients admitted to hospital
(any cause).
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 5 Patients admitted to hospital (any cause)
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaccine >14 serotypes
Steentoft 2006 18/37 6/12 0.95 [ 0.26, 3.48 ]
2 Vaccine 14 or less serotypes
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.6. Comparison 1 Pneumococcal vaccine versus control, Outcome 6 Hospital admissions
(pneumonia).
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 6 Hospital admissions (pneumonia)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vaccine >14 serotypes
2 Vaccine 14 or less serotypes
Leech 1987 0.6836 (0.5578) 1.98 [ 0.66, 5.91 ]
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
Analysis 1.7. Comparison 1 Pneumococcal vaccine versus control, Outcome 7 Hospital admissions (all
causes).
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 7 Hospital admissions (all causes)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vaccine >14 serotypes
2 Vaccine 14 or less serotypes
Leech 1987 0.0088 (0.1704) 1.01 [ 0.72, 1.41 ]
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
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Analysis 1.8. Comparison 1 Pneumococcal vaccine versus control, Outcome 8 Emergency visits (upper
respiratory tract infection).
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 8 Emergency visits (upper respiratory tract infection)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vaccine >14 serotypes
2 Vaccine 14 or less serotypes
Leech 1987 0.258 (0.33) 1.29 [ 0.68, 2.47 ]
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
Analysis 1.9. Comparison 1 Pneumococcal vaccine versus control, Outcome 9 Emergency visits
(pneumonia).
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 9 Emergency visits (pneumonia)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vaccine >14 serotypes
2 Vaccine 14 or less serotypes
Leech 1987 -0.008 (0.325) 0.99 [ 0.52, 1.88 ]
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
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Analysis 1.10. Comparison 1 Pneumococcal vaccine versus control, Outcome 10 Emergency visits (lower
respiratory tract infection).
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 10 Emergency visits (lower respiratory tract infection)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vaccine >14 serotypes
2 Vaccine 14 or less serotypes
Leech 1987 -0.0033 (0.148) 1.00 [ 0.75, 1.33 ]
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
Analysis 1.11. Comparison 1 Pneumococcal vaccine versus control, Outcome 11 Emergency visits (any
cause).
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 11 Emergency visits (any cause)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vaccine >14 serotypes
2 Vaccine 14 or less serotypes
Leech 1987 0.14 (0.104) 1.15 [ 0.94, 1.41 ]
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
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Analysis 1.12. Comparison 1 Pneumococcal vaccine versus control, Outcome 12 Death from cardio-
respiratory causes, 6-48 months post vaccine.
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 12 Death from cardio-respiratory causes, 6-48 months post vaccine
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaccine >14 serotypes
Alfageme 2006 33/298 30/298 68.7 % 1.11 [ 0.66, 1.88 ]
Subtotal (95% CI) 298 298 68.7 % 1.11 [ 0.66, 1.88 ]
Total events: 33 (Pneumococcal Vaccine), 30 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
2 Vaccine 14 or less serotypes
Davis 1987 8/50 7/53 14.7 % 1.25 [ 0.42, 3.75 ]
Leech 1987 5/92 7/97 16.6 % 0.74 [ 0.23, 2.42 ]
Subtotal (95% CI) 142 150 31.3 % 0.98 [ 0.44, 2.18 ]
Total events: 13 (Pneumococcal Vaccine), 14 (Control)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 440 448 100.0 % 1.07 [ 0.69, 1.66 ]
Total events: 46 (Pneumococcal Vaccine), 44 (Control)
Heterogeneity: Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
0.1 0.2 0.5 1 2 5 10
Favours vaccination Favours placebo
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Analysis 1.13. Comparison 1 Pneumococcal vaccine versus control, Outcome 13 Death from all causes, 6-
48 months post vaccine.
Review: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 13 Death from all causes, 6-48 months post vaccine
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaccine >14 serotypes
Alfageme 2006 57/298 58/298 71.1 % 0.98 [ 0.65, 1.47 ]
Subtotal (95% CI) 298 298 71.1 % 0.98 [ 0.65, 1.47 ]
Total events: 57 (Pneumococcal Vaccine), 58 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 Vaccine 14 or less serotypes
Davis 1987 14/50 13/53 13.8 % 1.20 [ 0.50, 2.88 ]
Leech 1987 6/92 11/97 15.2 % 0.55 [ 0.19, 1.54 ]
Subtotal (95% CI) 142 150 28.9 % 0.86 [ 0.44, 1.66 ]
Total events: 20 (Pneumococcal Vaccine), 24 (Control)
Heterogeneity: Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.46 (P = 0.64)
Total (95% CI) 440 448 100.0 % 0.94 [ 0.67, 1.33 ]
Total events: 77 (Pneumococcal Vaccine), 82 (Control)
Heterogeneity: Chi2 = 1.38, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
0.1 0.2 0.5 1 2 5 10
Favours vaccination Favours placebo
WH A T ’ S N E W
Last assessed as up-to-date: 20 July 2006.
Date Event Description
31 July 2008 Amended Converted to new review format.
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H I S T O R Y
Protocol first published: Issue 1, 1999
Review first published: Issue 4, 2006
Date Event Description
21 July 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Cates:
review of protocol, editing
Lasserson:
technical support, electronic searches of Cochrane registers, data extraction
Poole:
development of protocol, selection of studies, data checking, editing
Wood-Baker:
development of protocol, selection of studies, data extraction, data entry, analysis, interpretation
Walters:
selection of studies, data extraction
Granger:
selection of studies, data extraction, data entry, analysis, interpretation, writing up of review
Mangtani:
selection of studies, data extraction
D E C L A R A T I O N S O F I N T E R E S T
None known.
34Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S O U R C E S O F S U P P O R T
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